An Open Label Study of the Effects and Safety of Zanubrutinib in NMOSDs Adult Patients
An Open Label Trial Evaluating the Efficacy and Safety of Bruton's Tyrosine Kinase (BTK) Inhibitor Zanubrutinib in Adult Patients With Neuromyelitis Optical Spectrum Disorders (NMOSDs)
Sponsor: Xuanwu Hospital, Beijing
Terminated
Difficult in participant recruiting
Other terminated trials from Xuanwu Hospital, Beijing
Other Neuromyelitis Optica trials with similar outcome
A observational or N/A phase clinical study on Neuromyelitis Optica, this trial is terminated or withdrawn. The trial is conducted by Xuanwu Hospital, Beijing and has accumulated 5 data snapshots since 2022. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.
Study Description(click to expand)This is an open, single-center clinical study to evaluate the efficacy and safety of Zanubrutinib in the treatment of recurrent neuromyelitis optica spectrum disease. Patients were required to be diagnosed with neuromyelitis optic spectrum disease according to the NMOSD diagnostic criteria established by the international NMO Diagnostic Group (IPND) in 2015, and to have had at least two relapses (including first episode) within two years while at least one relapse occurring within the 12 months prior to screening. The AQP4 antibody must be positive during screening.
This is an open, single-center clinical study to evaluate the efficacy and safety of Zanubrutinib in the treatment of recurrent neuromyelitis optica spectrum disease. Patients were required to be diagnosed with neuromyelitis optic spectrum disease according to the NMOSD diagnostic criteria established by the international NMO Diagnostic Group (IPND) in 2015, and to have had at least two relapses (including first episode) within two years while at least one relapse occurring within the 12 months prior to screening. The AQP4 antibody must be positive during screening.
Status Flow
Change History
5 versions recorded-
Apr 28, 2026 — Present [daily]
Terminated
Status: Unknown → Terminated · Phase: PHASE2 → None
-
Nov 2024 — Apr 2026 [monthly]
Unknown PHASE2
Status: Recruiting → Unknown
-
Sep 2024 — Nov 2024 [monthly]
Recruiting PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Recruiting PHASE2
-
Jun 2022 — Jul 2024 [monthly]
Recruiting PHASE2
First recorded
May 2022
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
This is an open-label study, to evaluate the efficacy and safety of a BTK inhibitor zanubrutinib in participants with NMOSDs.
Contact Information
- Xuanwu Hospital, Beijing
For direct contact, visit the study record on ClinicalTrials.gov .